Has John Pitcher, MD received payments from drug or device companies?

Yes. Drug and device makers reported $306,836 in general payments to John Pitcher, MD across 232 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Pitcher, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Pitcher, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Pitcher, MD

Ophthalmology · Albuquerque, NMNPI 1538312582

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $190,076 of the $306,836 with a category attached, or 61.9%. 18 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 57.2% of the total. Among ophthalmology clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$306,836in general payments, 2019–2025

Across 232 payments — averaging $1322.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Regeneron Healthcare Solutions, Inc.$175K
Genentech USA, Inc.$92K
Novartis$20K
Regeneron$16K
Oyster Point Pharma, Inc.$2K
Apellis Pharmaceuticals, Inc.$332
plus $647 from 12 others

$2,359,536in research payments, 2019–2025

Across 845 payments — averaging $2792.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Regeneron$573K
Genentech, Inc.$459K
Ocular Therapeutix, Inc.$261K
Bayer$241K
Apellis Pharmaceuticals, Inc.$202K
Boehringer Ingelheim$181K
plus $443K from 9 others

What the payments were for

Consulting fees$86,69028%
Speaking & faculty fees$190,07662%
Travel & lodging$24,3658%
Food & beverage$5,6612%
Education$430%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Regeneron Healthcare Solutions, Inc.	101	$175,484
Genentech USA, Inc.	78	$92,122
Novartis	19	$20,324
Regeneron	5	$15,847
Oyster Point Pharma, Inc.	1	$2,080
Apellis Pharmaceuticals, Inc.	6	$332
Alcon	5	$185
Genentech, Inc.	4	$102
Alimera Sciences, Inc.	1	$94
AstraZeneca	1	$43
Biogen	2	$41
AbbVie	2	$40
Ocular Therapeutix, Inc.	1	$32
Astellas Pharma US Inc	2	$31
Bausch & Lomb Americas Inc.	1	$24
Amgen	1	$22
Spark Therapeutics, Inc.	1	$18
Halozyme Inc	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EYLEA$99,076
EYLEA HD$95,875
VABYSMO$46,218
Lucentis$44,790
BEOVU$14,640
TYRVAYA$2,080
SUSVIMO$142
Constellation$115
Syfovre$105

How this compares

$306,836 in reported general payments places this provider in the 95th percentile of 81 ophthalmology providers in New Mexico.

See all ophthalmology providers in New Mexico →

Medicare billing

Part B allowed, 2024

$7,785,994

Medicare patients

1,096

Services billed

138,932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	272	$9,366
Cyclosporine	13	$3,149
Latanoprost	180	$2,488
Ketorolac Tromethamine	69	$2,193
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	82	$1,756
Brimonidine Tartrate	148	$1,485
Difluprednate	12	$1,148
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim	120	$1,110
Dorzolamide Hcl	54	$991
Timolol Maleate	82	$909
Ofloxacin	32	$389
ErythromycinErythromycin Base	12	$156
Prednisone	26	$146
Diclofenac Sodium	13	$121

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Albuquerque

Robert MelendezAlbuquerque$349K
Christopher RoybalAlbuquerque$51K
Stephen ColemanAlbuquerque$12K
Rachel DavisAlbuquerque$10K
Ian ThompsonAlbuquerque$10K
Paul SanchezAlbuquerque$8K
Iuri GolubevAlbuquerque$7K
Thomas GilletteAlbuquerque$6K
Kenneth DownesAlbuquerque$5K
Arup DasAlbuquerque$5K

See the full list for New Mexico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →